| Page 1847 | Kisaco Research
 

Sid Salvi

Co-Founder & COO
Atolla

Mr. Liu is the Senior Vice President and General Manager at Perfect Corp.

 

Mr. Liu has been in his current position since June 2015. He has built the ground work for Perfect by recruiting key talent, establishing partnership with beauty brands, retailers such as L’Oréal, Estee Lauder, Target and other highly inferential organizations.  

 

Read full bio

Sid Salvi

Co-Founder & COO
Atolla

Sid Salvi

Co-Founder & COO
Atolla

Mr. Liu is the Senior Vice President and General Manager at Perfect Corp.

 

Mr. Liu has been in his current position since June 2015. He has built the ground work for Perfect by recruiting key talent, establishing partnership with beauty brands, retailers such as L’Oréal, Estee Lauder, Target and other highly inferential organizations.  

 

Prior to Perfect Corp, Mr. Liu joined Perfect’s parent company CyberLink in 2009. He was responsible for key partner development, sales strategy and business growth. He grew several multi-million dollars global OEM accounts and managed heavy weight industrial partners for such as Lenovo, Intel, Qualcomm, Time Warner., Comcast, DirecTV …

Mr. Liu has worked in various engineering and marketing management position at Intel, Broadcom and NVIDIA before joining Cyberlink.

 

Mr. Liu graduated from National Tsing Hua University in Taiwan in June 1992 with a Bachelor of Science degree. He completed his Masters of Science degree from Case Western Reserve University in June 1994. After receiving Master Degree, he continued pursuing advanced study by attending Electrical Engineering Ph.D. program at University of Southern California. Later, in order to learned more business knowledge, he earned his MBA Degree in Finance from Santa Clara University in June 2011. 

 

 

 

 
CAR-T Congress EU 2020
28-30 Jan 2020
London, United Kingdom
Be part of the movement as CAR-T Therapy shapes the future of oncology.The promise of the revolutionary oncology treatment, CAR-T therapy, has become a reality this year, with end-stage cancer patients treated on public health services across the world. As CAR-T moves into the public domain, battle has commenced in the race to effectively commercialise this ground-breaking therapy.The CAR-T Congress is bringing together leading biotechs, late-stage researchers and global pharmaceutical leaders to promote and share research that will break down barriers in R&D through novel data. In our fourth annual congress, we are introducing a new pre-day focused on NK Cell Therapy and the event will run alongside our Vein-to-Vein Congress, so you can tailor your agenda and learn more about cell therapies and their manufacturing. Having listened to the market demands, this year we will be bringing you even more industry-driven understanding of translational applications of the science that drives R&D in CAR-T. Tackle the next hurdles for allogeneic treatments by limiting graft vs host disease through the use of iPSC, and increase the efficacy of these treatments in solid tumours through combination therapies and solid tumour manipulation.Talks run by biotechs, pharma and regulatory bodies, will put you in a position to make informed decisions when commercialising your CAR-T therapy.
Visit Site
 
Phage Futures Europe
23-24 Nov 2021
Brussels, Belgium
Join us for the return of Phage Futures Europe, this November 2021 in Brussels, as we continue all-important discussions on translating new phage-based applications into clinical studies and beyond. Network and learn from multinational pharma, emerging biotechs, leading academics, investment representatives and regulatory bodies to discover how you can be at the forefront of the developing phage therapy market.Introducing face-to-face interactions once again, Phage Futures Europe will help you maximise networking and commercial development with key industry players such as GSK, BiomX, Contrafect and more. This year, we discuss the viability of phage derived lysines in therapy, assess the therapeutic application of natural phages vs engineered phages and explore the clinical data surrounding the magisterial and compassionate use of phages in Europe. Bacteriophages have seen continued investment and have adapted to global challenges, introducing commercial and marketable prospects for phage application. Phage Futures Europe explores the commercial applications of phages in poultry, aquaculture, biocontrol and skin microbiome, providing insights into the global design of phage products and acquiring pharmaceutical partnerships.
Visit Site
 

Christopher Mason

Weill Cornell Medicine

Christopher Mason

Weill Cornell Medicine

Christopher Mason

Weill Cornell Medicine
 
Phage Futures 2021
24-26 Feb 2021
Virtual Congress
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.Discover how you can be at the forefront of the developing phage therapy market.Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies. Among other topics, expect to hear & participate in:Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.Expert advice on how to find & secure financial investments.
Visit Site
Europe Pet Industry Primer
 
Skin Microbiome EU 2019
13-14 Nov 2019
London, United Kingdom
With 2.35 billion Euros being spent on cosmetic product R&D in Europe, are you ready for the next generation of skin care?Skin Microbiome continues it's reign as the 'biggest skincare trend' of the last two years, according to major market researchers and beauty bibles alike.  This year, we present the first dual-track, data-focused skin microbiome congress:Data Track: focuses on the hard data that supports and legitmises product and research claims while driving increased understanding of the skin microbiome.Commercial Track: tackles the challenges faced when building a commercially viable skin microbiome company, optimising your supply chain and executing successful communication strategies.Discover the potential of prebiotic, probiotic and postbiotic products being developed to protect and promote a healthy microbiome and ultimately combat dermatological conditions from acne and eczema to dandruff and skin allergies. Don't miss your chance to understand the next generation of skincare products!
Visit Site
 

Brian Burke

Head of Strategy
Horizon Discovery

Brian joined Horizon in 2012 during which time he has led various functions including Sales, Business Development and Product Management.  Much of his career has been focused in driving both the NGS and gene editing revolutions, most notably in the fields of diagnostics and bioprocessing.  In 2018 he was promoted to the Global Head of Strategy and now leads Horizon’s Corporate Development efforts including strategy development and M&A. 

Read full bio

Brian Burke

Head of Strategy
Horizon Discovery

Brian Burke

Head of Strategy
Horizon Discovery

Brian joined Horizon in 2012 during which time he has led various functions including Sales, Business Development and Product Management.  Much of his career has been focused in driving both the NGS and gene editing revolutions, most notably in the fields of diagnostics and bioprocessing.  In 2018 he was promoted to the Global Head of Strategy and now leads Horizon’s Corporate Development efforts including strategy development and M&A.